Pharmacy Plus Injectable Drug Recall Due to Sterility Assurance Failure
Pharmacy Plus, Inc. recalled a compounded injectable medication (56 vials) due to manufacturing processes that cannot guarantee product sterility. Distributed in Alabama, Louisiana, Mississippi, and Tennessee.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves compounded injectable medications with manufacturing processes that cannot assure sterility. The potential for microbial contamination of injectables presents a significant health risk despite no illnesses or injuries being reported to date.
Plain-English summary
Pharmacy Plus, Inc. dba Vital Care Compounder is recalling 56 vials of PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN injectable solution (150MG / 2.5MG / 50MCG in 5mL vials). This is a prescription-only medication produced as a sterile compounded product.
FDA inspection revealed that the manufacturing process used to produce these vials does not provide adequate assurance that the final product is sterile, as claimed. Sterility is critical for injectable medications, as any microbial contamination could cause serious infection or other adverse health effects.
The recalled lots are Lot 64409 (beyond-use date 04/08/2023) and Lot 60849 (beyond-use date 05/23/2023). These products were distributed to healthcare facilities in Alabama, Louisiana, Mississippi, and Tennessee.
Healthcare providers who have received these vials should stop use immediately and contact their distributor or Pharmacy Plus, Inc. (located at 115 S. 40th Ave., Hattiesburg, MS 39402) for recall information and guidance on appropriate action.
The recalled product
- Product
- PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN 150MG / 2.5MG / 50MCG SOLUTION, 5 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402
- Manufacturer
- Pharmacy Plus, Inc. dba Vital Care Compounder
- Category
- Drug — Compounded Injectable
- Affected units
- 56
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 64409
- BUD: 04/08/2023
- 60849
- BUD: 05/23/2023
Distribution
Part of a larger recall action
This product is one of 32 recalled by Pharmacy Plus, Inc. dba Vital Care Compounder under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 32 products in this recall →Related recalls
Same manufacturer · Pharmacy Plus, Inc. dba Vital Care Compounder
See all →- HighCompounded Semaglutide Injection Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-04-26
- HighGlycerin Ophthalmic Drops Recalled Due to Sterility Manufacturing Concerns
FDA (Drugs) · 2022-11-09
- HighPrescription Injectable Medication Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighFDA Recalls Vital Care Autologous Tears Serum Due to Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighInjectable hormone medication recalled for sterility assurance failure
FDA (Drugs) · 2022-11-09
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22